8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 26, 2010

Orchid Cellmark Inc.

(Exact name of the registrant as specified in its charter)

Delaware	000-30267	22-3392819
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4390 US Route One, Princeton, NJ 08540

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (609) 750-2200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 26, 2010, the Board of Directors of Orchid Cellmark Inc. (the “Company”) elected Bruce D. Dalziel to the Board of Directors as a Class II director effective April 1, 2010. As a Class II director, Mr. Dalziel will serve a term expiring in 2011.

Mr. Dalziel currently serves as chief financial officer at Medidata Solutions where he leads all aspects of finance, including control, financial reporting, tax, treasury, M&A, and internal audit, as well as legal, risk management, and investor relations. He was also chief financial officer for BISYS Inc., an outsourcing provider to the financial services industry, and DoubleClick, a global internet advertising solutions company. Earlier in his career, Mr. Dalziel held an array of finance positions with Prudential Life Insurance, rising to corporate vice president, financial planning and analysis. A 1992 graduate of Columbia University’s Executive MBA Program, he earned bachelor degrees from both Georgia Tech and Ursinus College of Pennsylvania

Mr. Dalziel will be compensated in accordance with the Company’s standard compensation policies and practices for its Board of Directors as follows: an annual retainer of $12,500 and $3,000 for each Board meeting attended or $500 per hour for telephonic Board meetings; and an initial grant of $100,000 of non-qualified stock options upon joining the Board (the number of options being determined based upon the 30-day trailing average stock price) and an annual grant of $75,000 of non-qualified stock options. For a more detailed discussion of the Company’s compensation policies for directors, please see the Company’s proxy statement dated September 8, 2009.

There is no family relationship, arrangement or understanding between Mr. Dalziel and any other person pursuant to which he was selected as a director of the Company.

A copy of the press release announcing the election of Mr. Dalziel is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated March 31, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Orchid Cellmark Inc.
Date: March 31, 2010	By:	/s/ William J. Thomas
	Name:	William J. Thomas
	Title:	Vice President and General Counsel

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated March 31, 2010

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:

Investors:	Media:
Thomas Bologna, CEO	Ed Orgon
Orchid Cellmark Inc.	The Torrenzano Group
(609) 750-2324	(212) 681-1700
ir@orchid.com	ed@torrenzano.com

BRUCE DALZIEL TO JOIN

ORCHID CELLMARK BOARD OF DIRECTORS

PRINCETON, N.J. — March 31, 2010 - Orchid Cellmark Inc. (Nasdaq: ORCH), a leading international provider of identity DNA testing services, today announced that Bruce D. Dalziel will join its Board of Directors effective April 1, 2010. Currently executive vice president and chief financial officer for a clinical development technology company with global operations, Mr. Dalziel brings considerable financial expertise to the Orchid Cellmark board, based on nearly 30 years financial management experience, including a decade in public company CFO roles.

“Bruce’s experience and expertise will be a valuable asset as Orchid implements its corporate growth strategies,” said James Beery, the company’s Board chairman. “His experience with technology companies and the array of financial matters they face will serve Orchid well as the company moves forward,” Mr. Beery explained.

Mr. Dalziel currently serves as chief financial officer at Medidata Solutions where he leads all aspects of finance, including control, financial reporting, tax, treasury, M&A, and internal audit, as well as legal, risk management, and investor relations. He was also chief financial officer for BISYS Inc., an outsourcing provider to the financial services industry, and DoubleClick, a global internet advertising solutions company. Earlier in his career, Mr. Dalziel held an array of finance positions with Prudential Life Insurance, rising to corporate vice president, financial planning and analysis.

A 1992 graduate of Columbia University’s Executive MBA Program, he earned bachelor degrees from both Georgia Tech and Ursinus College of Pennsylvania.

“Joining Orchid at this point in its development is exciting,” explained Mr. Dalziel. “The company is a clear market leader in DNA identity testing services and offers great promise. I look forward to working with my colleagues on the Board and the management team,” he concluded.

1

About Orchid Cellmark

Orchid Cellmark (Nasdaq: ORCH) is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. The company provides DNA family relationship testing to numerous child services organizations and individuals seeking to verify parentage. Orchid Cellmark also serves immigration and security authorities for DNA testing of individuals. In the agriculture field, the company provides DNA testing services for selective trait breeding. Orchid Cellmark’s strong market positions in these areas reflect the company’s accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the company’s reputation for exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at www.orchidcellmark.com.

Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press release.

2